<DOC>
	<DOCNO>NCT01049815</DOCNO>
	<brief_summary>Aims multi-center , randomize , treatment-controlled clinical trial compare efficacy sevelamer hydrochloride calcium-containing phosphorus binder reduce rate progression femoral carotid intimal medium thickness ( IMT ) thicken measure B-mode ultrasound stable maintenance hemodialysis ( HD ) patient .</brief_summary>
	<brief_title>Sevelamer Hydrochloride Femoral Carotid Intima Media Thickness Progression End Stage Renal Disease</brief_title>
	<detailed_description>Serum phosphorus ( P ) frequently elevate HD patient . Serum P stimulate PTH synthesis associate secondary hyperparathyroidism . Use calcium ( Ca ) -containing phosphorus-binders exogenous source Ca elevate CaxP product . In HD patient , ultrasonographically-demonstrated increase intima medium thickness carotid artery associate elevate serum P levels.Peripheral arterial vascular disease ( PVD ) account significant mortality morbidity HD patient . The aim study compare efficacy sevelamer hydrochloride calcium-containing phosphorus binder reduce rate progression femoral carotid intimal medium thickness ( IMT ) thicken measure B-mode ultrasound stable HD patient . Subject randomization number provide Epidemiology Research Unit , E. Wolfson Medical Center , Holon , Israel . After meet inclusion criterion , subject randomize one two treatment group : Renagel calcium carbonate . Prior receive treatment , baseline femoral carotid IMT measure , medical pharmaceutical history document , nutrition assessment undertaken midweek blood chemistry blood count measure . No change patient medication prescription require study , exception phosphorus binder . All concomitant medication continue . During year study , routine monthly blood test obtain chemistry , blood count , PTH measure every 4 month . After year treatment , femoral carotid IMT measure , midweek blood chemistry blood count measure .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Sevelamer</mesh_term>
	<mesh_term>Calcium Carbonate</mesh_term>
	<criteria>HD Patients age 4075 year inclusive receive HD treatment three time week less three month , treat sevelamer hydrochloride . Patients gender , without regard diabetes status , history CVD underlie renal disease eligible . Patients receive treatment sevelamer hydrochloride eligible study participation . Additionally , patient exclude active liver disease , know sensitivity either sevelamer hydrochloride calcum carbonate participation study deem way detrimental unwarranted patient 's treating physician .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>hemodialysis</keyword>
	<keyword>intimal medium thickness</keyword>
</DOC>